Analysis & Opinions
November 15, 2012
Following the third quarter earnings release, we are maintaining our long-term 'Neutral' recommendation on DexCom ...
November 05, 2012
DexCom (DXCM), a player in the glucose monitoring market, reported third quarter 2012 loss per share of 25 cents, ...
August 27, 2012
We reiterate our Neutral recommendation on DexCom Inc. (DXCM). Its second-quarter 2012 loss per share of 21 cents ...
August 07, 2012
DexCom (DXCM), a player in the glucose monitoring market, reported second-quarter 2012 loss per share of 21 cents, ...
June 15, 2012
DexCom (DXCM), a player in the glucose monitoring market, recently reported that it received a CE Mark for its 4th ...
June 14, 2012
On June 13, Echo Therapeutics (ECTE), a transdermal medical device company, announced that it anticipates being ...
June 11, 2012
We remain Neutral on DexCom (DXCM). Its first-quarter 2012 loss per share of 21 cents exceeded the Zacks Consensus ...
March 09, 2011
DexCom shows that, although times are tough, people will still adopt better technology.
December 28, 2010
The year's top performers in a tough medical device sector.
December 08, 2010
In a surprise decision, an FDA panel votes to approve Contrave, Orexigen's new obesity drug.
November 09, 2010
2010 has been a rough year in the diabetes space.
July 07, 2010
These seven med-tech stocks are blazing a growth trail through their markets.
June 25, 2010
Gaining exposure to the micro-cap sector through ETFs and individual stocks.
January 25, 2010
The recent positive activity of these stocks points to strong investment potential.